<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Amiodarone</id>
	<title>Amiodarone - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://scemsprotocols.com/scems/index.php?action=history&amp;feed=atom&amp;title=Amiodarone"/>
	<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Amiodarone&amp;action=history"/>
	<updated>2026-04-05T06:35:51Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://scemsprotocols.com/scems/index.php?title=Amiodarone&amp;diff=1387&amp;oldid=prev</id>
		<title>Treloars: Created page with &quot;==Section 8 - MEDICATION GUIDELINES== ===ANTIARRHYTHMICS===   ====Amiodarone / Antiarrhythmic==== &#039;&#039;&#039;DESCRIPTION:&#039;&#039;&#039; * Class III antidysrhythmic that prolongs the cardiac acti...&quot;</title>
		<link rel="alternate" type="text/html" href="https://scemsprotocols.com/scems/index.php?title=Amiodarone&amp;diff=1387&amp;oldid=prev"/>
		<updated>2020-04-23T23:34:58Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Section 8 - MEDICATION GUIDELINES== ===ANTIARRHYTHMICS===   ====Amiodarone / Antiarrhythmic==== &amp;#039;&amp;#039;&amp;#039;DESCRIPTION:&amp;#039;&amp;#039;&amp;#039; * Class III antidysrhythmic that prolongs the cardiac acti...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Section 8 - MEDICATION GUIDELINES==&lt;br /&gt;
===ANTIARRHYTHMICS===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
====Amiodarone / Antiarrhythmic====&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;DESCRIPTION:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Class III antidysrhythmic that prolongs the cardiac action potential and repolarization phase of the cardiac cycle. It shows beta-blocker and potassium channel blocker properties thus reducing dysrhythmias. It has complex drug effects on sodium and potassium.&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;INDICATIONS:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Ventricular Fibrillation]], [[Ventricular Fibrillation Pulseless Ventricular Tachycardia|Pulseless V-Tach]] (4.08), [[Ventricular Tachycardia with a Palpable Pulse|V-Tach with a pulse]] (4.09).&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;CONTRAINDICATIONS:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Sinus bradycardia, AV blocks.&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;PRECAUTIONS:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Not recommended for pregnant or nursing mothers.&lt;br /&gt;
* Multiple drug interactions – interacts with digoxin, warfarin, phenytoin.&lt;br /&gt;
* When given concurrently with simvastatin (cholesterol drugs) it increases the risk for rhabdomyolysis and renal failure.&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;DOSAGE:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Adult&lt;br /&gt;
** VF/VT – 300 mg IVP, IO. May repeat once with 150 mg IVP, IO if dysrhythmia is not suppressed with initial dose.&lt;br /&gt;
** VT with a pulse – 150 mg diluted in 50 ml (Buretrol) over 10 minutes.&lt;br /&gt;
* Pediatric - Refer to Handtevy System for pediatric specific dosage.&lt;br /&gt;
** VF/VT - 5 mg/kg, can repeat dose in 5 mg/kg doses to max of 15 mg/kg total dose.&lt;br /&gt;
&lt;br /&gt;
[[Category:Medication Guidelines|Amiodarone ]]&lt;/div&gt;</summary>
		<author><name>Treloars</name></author>
	</entry>
</feed>